Cellectis Archives

Best in Biotech 22 Dec 2016

The 10 Biggest Clinical Success Stories of 2016 in European Biotech

What are the most impressive advances in medical biotechnology this year? From cancer to peanut allergy, here’s a list of the best success stories of 2016. Biotech is becoming a powerful driving force in medicine, providing innovative therapies that could end some of the most severe diseases. To celebrate the advances in the area of […]

December 22, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 14 Dec 2016

What do the CAR-T Patient Deaths Mean for the Future of the Field?

Juno’s JCAR015 study came to a halt for the second time this year after two more patient deaths. But despite the bad news, hopes for CAR-T therapies remain high. Juno Therapeutics again came under scrutiny last month following deaths in its JCAR015 trial. Two patients died from neurotoxicity-triggered cerebral edema, the same condition that killed […]

December 14, 2016 - 7 minutesmins - By Diana Kwon

News and Trends 5 Nov 2016

Would you Taste this Gene-Edited Dinner?

Genetic engineering can make food healthier, improve nutrition and reduce environmental impact. To demonstrate its potential, Cellectis hosted a dinner featuring futuristic food technology. Cellectis is a French company that develops immuno-oncology therapies and became famous last year when its CAR-T treatment saved a 1-year old girl from leukemia. Its gene-editing TALEN technology is also used by […]

November 5, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 29 Sep 2016

Debunking the Immuno-Oncology Hype: is it as good as it sounds?

CAR-T therapies have gained plenty of attention lately by promising to end cancer with a one-off treatment. But all that glitters is not gold; experts remind us it is important to be critical about the immuno-oncology hype. Immuno-oncology has become all the rage lately, and the hype has led to some major investments, acquisitions, deals and partnerships. It seems […]

September 29, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

car t cd19 fda juno therapeutics cerebral edema

News and Trends 18 Jul 2016

UPDATED: Storm on the CAR-T field – 3 patients die in Phase II Study

A CAR-T program in Phase II trials (from Juno Therapeutics) was suspended by the FDA after 3 deaths, which could be treatment-related. How will this impact the field, given that most CAR-T Biotechs share the same target? UPDATE (article originally published on 8/7/2016): the FDA has allowed Juno Therapeutics to resume its CAR-T trial with […]

July 18, 2016 - 5 minutesmins - By Denise Neves Gameiro

News and Trends 23 Jun 2016

Cellectis gets paid for a first Milestone, Investors are pleased

After successfully ‘saving’ two babies with terminal-stage acute Leukemia, Cellectis finally treated the first patient in its Phase I trial. A major milestone that could confirm the potential of its lead candidate UCART-19. It’s once again a success for the French biotech company! As it announced on Monday, the first patient has been treated in […]

June 23, 2016 - 2 minutesmins - By Jerome Topsent

blood cancer disease model, multi-omics, CAR-T, oncology

News and Trends 28 May 2016

It’s Blood Cancer Day, how is Biotech fixing it?

Today is the World Blood Cancer Day, an event to show solidarity to patients and raise awareness for the need of better therapies to treat these cancers – which are still often deadly. Blood cancers can affect different type of cells in the blood. Because these cells are so close to the circulatory and immune system, […]

May 28, 2016 - 4 minutesmins - By Denise Neves Gameiro

cellectis ucart leukemia cancer gmp manufacturing ucart19 ucart123 allogeneic universal 2015 financial results

News and Trends 16 Mar 2016

How Good was 2015 for the French Universal CAR-T Biotech?

Cellectis (France) has now released its financial results for 2015. What happened and what the prospects for 2016 and long-term? It was a really packed year for Cellectis, the French Champion for universal, off-the-shelf CAR-T treatments. The Biopharma saw significant advances in multiple fronts, from clinical development to financing. The first therapy initially developed by […]

March 16, 2016 - 3 minutesmins - By Denise Neves Gameiro

biotech nasdaq stock top biopharma finance 2016

News and Trends 23 Feb 2016

7 Trendy European Biotechs Listed on the NASDAQ in 2016

Here are 7 European Biotechs listed on the NASDAQ we thought were worth mentioning in more depth; location, market cap and brief financial and R&D backgrounds. NASDAQ is the second-largest Stock exchange in the world, based in New York, and the largest for high-tech companies. It seems to be the real test for a European biotech to […]

February 23, 2016 - 6 minutesmins - By Philip Hemme

DIRK BUSCH TECHNICAL UNIVERSITY MUNICH car t leukemia all

News and Trends 17 Feb 2016

Cancer: World Best Ever CAR-T Results have Just been Disclosed

These are the best results yet for CAR-T, this time from a research group led by Dirk Busch at the Technical University of Munich (Germany). In part backed by Juno Therapeutics, a method to select more potent T-cells and engineer a safety mechanism was announced at the annual meeting of the AAAS in Washington (US). CAR-T therapies are one of the ways […]

February 17, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 8 Feb 2016

The European Union Finances the Future of CAR-T Manufacturing

CAR-T is the way forward in Cancer therapeutics, which is one of the leading causes of Mortality in the Western world. Now this European consortium has amassed €6M for a more unified approach to CAR-T under a European Union Commission program. In response to this major health issue Miltenyi Biotec (Germany) coordinates the new EU-funded project […]

February 8, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 26 Jan 2016

2011-2015: What a Fantastic 5 Years for European Biotech

The crisis of 2008 hit the Biotech sector hard, and it wasn’t clear how the Biotech industry would get back on track. But now, end of 2015, we can definitely say the Biotech industry did extremely well and probably better than most of the analysts would have predicted… So what were the major news stories […]

January 26, 2016 - 5 minutesmins - By Philip Hemme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us